Range of eligible sufferers: CDEC discussed the uncertainty in the amount of sufferers with reasonably critical to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical authorities consulted by CADTH indicated that some sufferers who will be categorized as having delicate or average disease might have a significant bleeding https://simongklmu.blue-blogs.com/43417458/not-known-details-about-hemgenix